Review in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Benoit AguadoUniversité Paris-Saclay, French National Institute for Health and Medical Research, UMR_S 999, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), European Reference Network on Rare Respiratory Diseases, Fédération Hospitalo-Universitaire André Cournand, Le Plessis Robinson, France (B.A., G.R., T.L.-P., M.G., F.B., M.H., D.M., F.A.).ORCID 0009-0005-6895-194X
Grégoire RuffenachUniversité Paris-Saclay, French National Institute for Health and Medical Research, UMR_S 999, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), European Reference Network on Rare Respiratory Diseases, Fédération Hospitalo-Universitaire André Cournand, Le Plessis Robinson, France (B.A., G.R., T.L.-P., M.G., F.B., M.H., D.M., F.A.).ORCID 0000-0001-6419-4332
Thomas Lacoste-PalassetUniversité Paris-Saclay, French National Institute for Health and Medical Research, UMR_S 999, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), European Reference Network on Rare Respiratory Diseases, Fédération Hospitalo-Universitaire André Cournand, Le Plessis Robinson, France (B.A., G.R., T.L.-P., M.G., F.B., M.H., D.M., F.A.).ORCID 0000-0003-3543-6675
Agnes GörlachExperimental and Molecular Pediatric Cardiology, Department of Pediatric Cardiology and Congenital Heart Diseases, German Heart Center Munich at the Technical University Munich, Germany (A.G.).
Marianne RiouChest Diseases Department (M.R.), Nouvel Hôpital Civil, University Hospital of Strasbourg, France.ORCID 0000-0001-6807-8582
Mathieu GourmelonUniversité Paris-Saclay, French National Institute for Health and Medical Research, UMR_S 999, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), European Reference Network on Rare Respiratory Diseases, Fédération Hospitalo-Universitaire André Cournand, Le Plessis Robinson, France (B.A., G.R., T.L.-P., M.G., F.B., M.H., D.M., F.A.).ORCID 0009-0007-7625-0048
Fabrice BauerUniversité Paris-Saclay, French National Institute for Health and Medical Research, UMR_S 999, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), European Reference Network on Rare Respiratory Diseases, Fédération Hospitalo-Universitaire André Cournand, Le Plessis Robinson, France (B.A., G.R., T.L.-P., M.G., F.B., M.H., D.M., F.A.).ORCID 0000-0002-9221-9688
Marc HumbertUniversité Paris-Saclay, French National Institute for Health and Medical Research, UMR_S 999, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), European Reference Network on Rare Respiratory Diseases, Fédération Hospitalo-Universitaire André Cournand, Le Plessis Robinson, France (B.A., G.R., T.L.-P., M.G., F.B., M.H., D.M., F.A.).ORCID 0000-0003-0703-2892
Valerie Schini-KerthTranslational Cardiovascular Medicine UR 3074, Fédération de Médecine Translationnelle de Strasbourg, France (V.S.-K.).ORCID 0000-0001-9997-9287
Jean-Luc VachiéryDepartment of Cardiology, Cliniques Universitaires de Bruxelles-Hôpital Erasme, Belgium (J.-L.V.).ORCID 0000-0002-6358-7852
David MontaniUniversité Paris-Saclay, French National Institute for Health and Medical Research, UMR_S 999, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), European Reference Network on Rare Respiratory Diseases, Fédération Hospitalo-Universitaire André Cournand, Le Plessis Robinson, France (B.A., G.R., T.L.-P., M.G., F.B., M.H., D.M., F.A.).ORCID 0000-0002-9358-6922
Fabrice AntignyUniversité Paris-Saclay, French National Institute for Health and Medical Research, UMR_S 999, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), European Reference Network on Rare Respiratory Diseases, Fédération Hospitalo-Universitaire André Cournand, Le Plessis Robinson, France (B.A., G.R., T.L.-P., M.G., F.B., M.H., D.M., F.A.).ORCID 0000-0002-9515-6571
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Inhibiting SGLT2 (sodium-glucose cotransporter 2) has recently transformed the medical care of patients with left heart disease. Right ventricular failure is a major predictor for patients suffering from pulmonary hypertension of various causes, including those with postcapillary pulmonary hypertension due to left heart disease. Similar to how SGLT2 inhibition benefits patients with left heart failure, recent studies have suggested utilizing these molecules to enhance right ventricular function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of SGLT2is (SGLT2 inhibitors) in pulmonary hypertension. Further dedicated trials are necessary to establish their role in right ventricular pulmonary vascular disease.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.